奥拉帕利联合一线化疗在铂敏感复发性上皮性卵巢癌患者中的应用  

Application of Olaparib Combined with First-Line Chemotherapy in Platinum Sensitive Recurrent Epithelial Ovarian Cancer Patients

作　　者：郭双双[1] GUO Shuangshuang(Department of Oncology,the First Affiliated Hospital of Henan University of Science and Technology,Luoyang 471000,China)

机构地区：[1]河南科技大学第一附属医院肿瘤科,河南洛阳471000

出　　处：《河南医学研究》2025年第2期333-336,共4页Henan Medical Research

摘　　要：目的分析奥拉帕利联合一线化疗(紫杉醇+卡铂)在铂敏感复发性上皮性卵巢癌(ROC)患者中的应用效果。方法本研究采用前瞻性随机对照分析,纳入2021年6月至2022年6月河南科技大学第一附属医院收治的80例铂敏感ROC患者为研究对象,根据随机、双盲的原则分为观察组[40例,一线化疗(紫杉醇+卡铂)方案+安慰剂+奥拉帕利]和对照组[40例,一线化疗方案+安慰剂],两组均持续治疗直至疾病进展或发生不可接受的不良反应。比较两组临床疗效、生存情况以及治疗期间不良反应发生情况。结果观察组客观缓解率及疾病控制率高于对照组(P<0.05);经Kaplan-Meier生存分析显示,观察组中位无进展生存期(PFS)、中位总生存期(OS)长于对照组(P<0.001);两组不良反应程度比较,差异无统计学意义(P>0.05)。结论相较于单纯的TC方案化疗,奥拉帕利联合TC方案在铂敏感ROC患者中应用效果更好,可有效延长患者生存期,且产生的3级及以上的不良反应较少。Objective To analyze the application effect of olaparib combined with first-line chemotherapy(paclitaxel+carboplatin)in platinum sensitive recurrent epithelial ovarian cancer(ROC)patients.Methods This study used a prospective randomized controlled analysis and included 80 platinum sensitive ROC patients admitted to the First Affiliated Hospital of Henan University of Science and Technology from June 2021 to June 2022 as the study subjects.According to the principle of random and double-blind,they were divided into observation group[40 cases,first-line chemotherapy(paclitaxel+carboplatin)regimen+placebo+olapali]and control group[40 cases,first-line chemotherapy regimen+placebo].Both groups continued to treat until the disease progressed or unacceptable adverse reactions occurred.The clinical efficacy,survival and adverse reactions during treatment were compared between the two groups.Results The objective response rate and disease control rate of the observation group were higher than those of the control group(P<0.05).According to Kaplan-Meier survival analysis,the median progression free survival(PFS)and the median overall survival(OS)in the observation group were significantly longer than those of the control group(P<0.001).There was no statistically difference in the degree of toxic side effects between the two groups(P>0.05).Conclusion Compared to simple TC regimen chemotherapy,the combination of olaparib and TC regimen is more effective in platinum sensitive ROC patients,effectively prolonging patient survival,and producing fewer grade 3 and above toxic side effects.

关 键 词：铂敏感复发性上皮性卵巢癌 奥拉帕利 紫杉醇 卡铂 

分 类 号：R737.3[医药卫生—肿瘤]